Category: News

For Immediate Release February 17, 2021

Phoenix, February 17th, 2021 (Newsfile Corp.) — The Stock Day Podcast welcomed  Sunshine Biopharma (SBFM)(“the Company”), a company engaged in the development of Adva-27a, a unique anticancer compound, as well as the development of a treatment for COVID-19. CEO of the Company, Dr. Steve Slilaty, joined Stock Day host Everett  Jolly.  

Jolly began the interview by commenting on the Company’s significant increase in stock  price over the past several months. “I think the market recognizes the significant  progress that we’ve been making, and we’re very excited about the science we’ve been  doing,” shared Dr. Slilaty.  

“Could you give us an update on the licensing agreement with the University of  Georgia?”, asked Jolly. “Initially, we teamed up with the University of Georgia because  they had worldwide renowned expertise in coronavirus protease inhibitors, and this is  what our coronavirus treatment is centered around,” explained Dr. Slilaty. “The  University of Georgia had two technologies which were already patented by them and  we agreed that they would license them to us on an exclusive basis. In return, we would  offer co-development of their compounds in parallel with our own.”  

Jolly then asked about the progress of the Company’s COVID-19 treatment. “We are  now at the stage where we have initiated mice studies on our SBFM-PL4 protease  inhibitor,” said Dr. Slilaty, adding that the Company will also be including the licensed  compounds from the University of Georgia in these studies. Dr. Slilaty then elaborated  on the process of the mice studies, as well as what would occur in the event of a  successful study. “If that were the case, we would file our results with the FDA and  request that the FDA authorizes us to proceed to test our compound on actual COVID 19 patients.” 

The conversation then turned to the Company’s development of Adva-27a. “So, that is  our flagship anticancer compound,” explained Dr. Slilaty. “It is the only drug we’re aware  of anywhere in the world that works on multidrug resistant cancer cells,” he shared.  “We’re really excited about this. We have ordered a new batch of Adva-27a, and we’re  expecting delivery of the new batch any time now,” said Dr. Slilaty, adding that the  Company intends to use the compound in mice studies. 

“What’s next for the COVID-19 research plan?”, asked Jolly. “At the end of the mice  studies, we’re going to file the data of the mice studies with the FDA and request a 

review of our results, as well as authorization to proceed with Phase I clinical trials on  actual COVID-19 patient volunteers,” explained Dr. Slilaty. “What’s interesting with our  drug is the fact that it can be taken orally at home. There is no need for a hospital  setting, as is the case right now with current treatments.” 

To close the interview, Dr. Slilaty thanked listeners and shareholders for their support  and interest as they continue to develop treatments for COVID-19 and cancer. “We  hope that we will make a difference in reducing the number of deaths not only in the  United States, but around the world.” 

To hear Dr. Steve Slilaty’s entire interview, follow the link to the podcast here:  https://audioboom.com/posts/7801741-sunshine-biopharma-discusses-the-progress-of-its covid-19-and-anticancer-compounds-with-the-stock 

Investors Hangout is a proud sponsor of “Stock Day,” and Stock Day Media encourages  listeners to visit the company’s message board at https://investorshangout.com/ 

About Sunshine Biopharma 

In addition, to working on the development of a treatment for COVID-19, Sunshine  Biopharma is engaged in the development Adva-27a, a unique anticancer compound.  Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying  Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung  Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for  Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish  General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and  intellectual property pertaining to Adva-27a. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current  expectations, forecasts, and assumptions that involve risks as well as uncertainties that  could cause actual outcomes and results to differ materially from those anticipated or 

expected, including statements related to the amount and timing of expected revenues  statements related to our financial performance, expected income, distributions, and  future growth for upcoming quarterly and annual periods. These risks and uncertainties  are further defined in filings and reports by the Company with the U.S. Securities and  Exchange Commission (SEC). Actual results and the timing of certain events could  differ materially from those projected in or contemplated by the forward-looking  statements due to a number of factors detailed from time to time in our filings with the  SEC. Among other matters, the Company may not be able to sustain growth or achieve  profitability based upon many factors including but not limited to general stock market  conditions. Reference is hereby made to cautionary statements set forth in the  Company’s most recent SEC filings. We have incurred and will continue to incur  significant expenses in our expansion of our existing as well as new service lines noting  there is no assurance that we will generate enough revenues to offset those costs in  both the near and long term. Additional service offerings may expose us to additional  legal and regulatory costs and unknown exposure(s) based upon the various  geopolitical locations we will be providing services in, the impact of which cannot be  predicted at this time. 

For Additional Information Contact: 

Camille Sebaaly, CFO 

Sunshine Biopharma Inc. 

Direct Line: 514-814-0464 

camille.sebaaly@sunshinebiopharma.com 

www.sunshinebiopharma.com

About The “Stock Day” Podcast 

Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and  Micro-Cap companies. It educates investors while simultaneously working with penny  stock and OTC companies, providing transparency and clarification of under-valued,  under-sold Micro-Cap stocks of the market. Stock Day provides companies with  customized solutions to their news distribution in both national and international media  outlets. The Stock Day Podcast is the number one radio show of its kind in America. 

SOURCE: 

Stock Day Media 

(602) 821-1102

For Immediate Release February 10, 2021

Montreal, Quebec, Canada — (ACCESSWIRE) — Sunshine Biopharma Inc. (OTC PINK: “SBFM”),  a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has initiated a momentous transgenic mice study of its COVID-19 treatment that has been under development since May of last year. 

Sunshine Biopharma’s COVID-19 treatment consists of a series of small molecules which suppress replication of the virus by inhibiting a key virus encoded protease that is responsible for compromising the immune system of infected patients. The mice studies are currently underway at the University of Georgia, College of Pharmacy. 

The mice being used in the study have been genetically engineered to express the human angiotensin-converting enzyme 2 (hACE2) transmembrane protein in their lungs making them susceptible to lethal infection by SARS-CoV-2, the causative agent of COVID-19. The SARS CoV-2 virus uses the hACE2 receptor to gain entry into human cells to replicate. The goal of the study is to determine if Sunshine Biopharma’s protease inhibitors will protect the hACE2- transgenic mice from disease progression and death following infection with SARS-CoV-2 virus. 

“Should these mice studies prove successful, we plan to submit the results to the FDA for authorization to conduct testing on actual COVID-19 patient volunteers in a Phase I clinical trial setting,” said Dr. Steve Slilaty, CEO of Sunshine Biopharma. “We are excited to have initiated this pivotal study on transgenic mice with the University of Georgia. The implications of a COVID-19  treatment becoming available are vast. This is particularly the case in view of the fact that some of the variants emerging around the world are more virulent and may escape neutralization by the current vaccines,” he added. 

About Sunshine Biopharma’s Coronavirus Treatment 

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the etiologic agent of the ongoing COVID-19 pandemic that has claimed the lives of over 2.3 million people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest the replication of the virus in people who have contracted the illness. On May 22, 2020, Sunshine  Biopharma filed a provisional patent application for several molecules which were designed by computer-aided modelling to inhibit the Coronavirus proteases, thus shutting down the ability of the virus to multiply. Sunshine Biopharma has since completed the synthesis of four such molecules and identified a lead compound, SBFM-PL4. In collaboration with the University of 

Georgia, College of Pharmacy, the Company is currently advancing the development of SBFM PL4 through the in vitro testing stage to be followed by mice studies, currently underway, before entering clinical trials on COVID-19 patients. 

About Sunshine Biopharma 

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine  Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at  McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is the owner of all patents and intellectual property pertaining to Adva-27a. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current expectations, forecasts, and  assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially  from those anticipated or expected, including statements related to the amount and timing of expected revenues  statements related to our financial performance, expected income, distributions, and future growth for upcoming  quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company  with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ  materially from those projected in or contemplated by the forward-looking statements due to a number of factors  detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain  growth or achieve profitability based upon many factors including but not limited to general stock market conditions.  Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC filings. We have  incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines  noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long  term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s)  based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted  at this time. 

For Additional Information Contact: 

Camille Sebaaly, CFO 

Sunshine Biopharma Inc. 

Direct Line: 514-814-0464 

camille.sebaaly@sunshinebiopharma.com 

www.sunshinebiopharma.com

For Immediate Release February 4, 2021

Montreal, Canada – (ACCESSWIRE) – Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a  pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that it has signed an exclusive license agreement  with the University of Georgia (“UGA”) for two Anti-Coronavirus compounds which UGA had  previously developed and patented. Sunshine Biopharma and UGA will advance the development  of these two compounds in parallel with Sunshine Biopharma’s own SBFM-PL4. The next step in  the development plan involves testing of the efficacy of these compounds in transgenic mice.  Mice which have been genetically engineered to become susceptible to infection by SARS-CoV 

2, the causative agent of COVID-19, will be challenged with the virus and subsequently treated with the test compounds to determine if progression to diseases can be arrested. Such studies  are anticipated to be underway later this month. 

“We are delighted to have reached this agreement with the University of Georgia,” said Dr. Steve  N. Slilaty, CEO of Sunshine Biopharma. “UGA’s compounds expand our war chest and enhance  our effort to hone in on a most effective treatment for COVID-19,” he added. 

About Sunshine Biopharma’s COVID-19 Treatment 

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the etiologic agent of  COVID-19, the current ongoing pandemic that has claimed the lives of over 2.2 million people  worldwide since it first appeared in December 2019. There are currently no drugs that can  effectively arrest replication of the virus in people who have contracted the illness. On May 22,  2020, Sunshine Biopharma filed a provisional patent application for a library of molecules which  were designed to inhibit the Coronavirus proteases, thus shutting down the ability of the virus to  multiply and cause illness. Sunshine Biopharma has since screened the library and identified a  lead Anti-Coronavirus compound (SBFM-PL4). The Company is currently conducting a series of  in vitro tests to evaluate its specific inhibitory activity of SBFM-PL4 against the SARS-CoV-2  papain-like protease (PLpro), one of two Coronavirus encoded proteases essential for viral  replication. Following the initial in vitro studies, SBFM-PL4 will be moved forward to the cell culture  testing stage and assessment in Coronavirus infected mice before entering human clinical trials. 

About Sunshine Biopharma 

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is  engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date 

have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine  Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at  McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner  of all patents and intellectual property pertaining to Adva-27a. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current expectations, forecasts, and  assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially  from those anticipated or expected, including statements related to the amount and timing of expected revenues  statements related to our financial performance, expected income, distributions, and future growth for upcoming  quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company  with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ  materially from those projected in or contemplated by the forward-looking statements due to a number of factors  detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain  growth or achieve profitability based upon many factors including but not limited to general stock market conditions.  Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC filings. We have  incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines  noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long  term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s)  based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted  at this time. 

For Additional Information Contact: 

Camille Sebaaly, CFO 

Sunshine Biopharma Inc. 

Direct Line: 514-814-0464 

camille.sebaaly@sunshinebiopharma.com 

www.sunshinebiopharma.com

For Immediate Release February 2, 2021

Montreal, Canada – (ACCESSWIRE) – Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a  pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that it has received a “Notice of Allowance” from  the Canadian Intellectual Property Office for a new patent application covering Adva-27a, the  Company’s flagship anticancer compound. This newly issued patent contains new subject matter  and extends the proprietary protection of Adva-27a in Canada until 2033. The equivalent patent  in the United States was issued in 2019 (US Patent Number 10,272,065) and similarly covers Adva-27a until 2033. The analogous patents are still pending in Europe. Sunshine Biopharma is  the sole owner of all intellectual property rights pertaining to Adva-27a, including the first Adva 27a patent (US Patent Number 8,236,935) issued in 2012. 

“We are very excited about this significant development for Adva-27a,” said Dr. Steve N. Slilaty,  CEO of Sunshine Biopharma. “Allowance of this patent application gives us 12 years of additional  protection and is a further validation of the uniqueness and innovative aspects of our lead  anticancer molecule,” he added. 

About Sunshine Biopharma’s Adva-27a 

Adva-27a is a unique anticancer compound targeted for multidrug resistant cancer. Tests  conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug  Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast  Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are  planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. 

About Sunshine Biopharma 

In addition, to working on the development of Adva-27a, Sunshine Biopharma is engaged in the  development in the development of a treatment COVID-19. Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has  claimed the lives of over 2.1 million people worldwide since it first appeared in December 2019.  There are currently no drugs that can effectively arrest replication of the virus in people who have  contracted the illness. On May 22, 2020, Sunshine Biopharma filed a provisional patent  application for several molecules which were designed by computer-aided modeling to inhibit the  Coronavirus proteases, thus shutting down the ability of the virus to multiply. Sunshine Biopharma  has since completed the synthesis of four such molecules and identified a lead compound, SBFM-

PL4. In collaboration with the University of Georgia, College of Pharmacy, the Company is  currently advancing the development of SBFM-PL4 through the in vitro testing stage to be  followed by mice studies before entering clinical trials on COVID-19 patients. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current expectations, forecasts, and  assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially  from those anticipated or expected, including statements related to the amount and timing of expected revenues  statements related to our financial performance, expected income, distributions, and future growth for upcoming  quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company  with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ  materially from those projected in or contemplated by the forward-looking statements due to a number of factors  detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain  growth or achieve profitability based upon many factors including but not limited to general stock market conditions.  Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC filings. We have  incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines  noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long  term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s)  based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted  at this time. 

For Additional Information Contact: 

Camille Sebaaly, CFO 

Sunshine Biopharma Inc. 

Direct Line: 514-814-0464 

camille.sebaaly@sunshinebiopharma.com 

www.sunshinebiopharma.com

For Immediate Release January 27, 2021

Montreal, Quebec, Canada — (ACCESSWIRE) — Sunshine Biopharma Inc. (OTC PINK:  “SBFM”), a pharmaceutical company focused on the research, development and  commercialization of oncology and antiviral drugs, today announced that it has successfully  completed and submitted the application to uplist to the OTCQB. While the Company is  currently a fully reporting issuer trading on OTC Markets PINK, management has determined  that an uplist to OTCQB is aligned with the Company’s overall growth trajectory as it will allow  institutional investors to participate. 

The OTCQB Venture Market, operated by OTC Markets Group Inc. in New York City, is a  premier market for early stage and developing companies. As a verified market with efficient  access to U.S. investors, OTCQB helps companies build shareholder value with a goal of  enhancing liquidity and achieving fair valuation. 

Sunshine Biopharma’s CFO, Camille Sebaaly, stated, “Joining the OTCQB is a pivotal  milestone for the Company and elevates Sunshine’s reputation among the investment  community. We would like to thank our shareholders for their continued support as the  Company has been steadily growing and making advancements in research and development.”  

About Sunshine Biopharma’s Coronavirus Treatment 

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 1.4 million people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest  replication of the virus in people who have contracted the illness. On May 22, 2020, Sunshine  Biopharma filed a provisional patent application for several molecules which were designed by  computer-aided modeling to inhibit the Coronavirus proteases, thus shutting down the ability of  the virus to multiply. Sunshine Biopharma has since completed the synthesis of four such  molecules and identified a lead compound, SBFM-PL4. In collaboration with the University of  Georgia, College of Pharmacy, the Company is currently advancing the development of SBFM PL4 through the in vitro testing stage to be followed by mice studies before entering clinical  trials on COVID-19 patients.

About Sunshine Biopharma 

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is  engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to  date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant  Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer  cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to  be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine  Biopharma is owner of all patents and intellectual property pertaining to Adva-27a. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current expectations, forecasts, and  assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ  materially from those anticipated or expected, including statements related to the amount and timing of expected  revenues statements related to our financial performance, expected income, distributions, and future growth for  upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by  the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain  events could differ materially from those projected in or contemplated by the forward-looking statements due to a  number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not  be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock  market conditions. Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC  filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as  new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the  near and long term. Additional service offerings may expose us to additional legal and regulatory costs and  unknown exposure(s) based upon the various geopolitical locations we will be providing services in, the impact of  which cannot be predicted at this time. 

For Additional Information Contact: 

Camille Sebaaly, CFO 

Sunshine Biopharma Inc. 

Direct Line: 514-814-0464 

camille.sebaaly@sunshinebiopharma.com 

www.sunshinebiopharma.com

For Immediate Release January 14, 2021

Montreal, Quebec, Canada — (ACCESSWIRE) — Sunshine Biopharma Inc. (OTC PINK: “SBFM”),  a pharmaceutical company focused on the research, development and commercialization of  oncology and antiviral drugs, today announced that it has received the fourth tranche of funding  under the recently announced committed minimum financing of $2,000,000 with RB Capital  Partners Inc. This brings the total to $1,050,000 that the Company has received to date under  this financing. The proceeds will be used for the ongoing development of the Company’s  Coronavirus Treatment on a priority basis and the clinical development of Adva-27a, the  Company’s flagship anticancer compound targeted for pancreatic cancer. 

Sunshine Biopharma Inc. CFO, Camille Sebaaly stated, “As a company, we continue to forge  forward in our development of a COVID treatment and our anticancer compounds. This  investment capital has been integral to our progress in each of these sectors.” 

Brett Rosen and Deborah Braun of RB Capital Partners Inc. stated, “We are very impressed with  the Sunshine leadership team and their commitment to developing critical life-saving medical  treatments. Our investment money has been met with ongoing milestones and we are pleased to  be considered a long-term funding partner of the Company. We are looking forward to a potential  up-list to the Nasdaq in the future.” 

About Sunshine Biopharma’s Coronavirus Treatment 

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 1.9 million people worldwide since  it first appeared in December 2019. There are currently no drugs that can effectively arrest  replication of the virus in people who have contracted the illness. On May 22, 2020, Sunshine  Biopharma filed a provisional patent application for several molecules which were designed by  computer-aided modeling to inhibit the Coronavirus proteases, thus shutting down the ability of  the virus to multiply. Sunshine Biopharma has since completed the synthesis of four such  molecules and identified a lead compound, SBFM-PL4. In collaboration with the University of  Georgia, College of Pharmacy, the Company is currently advancing the development of SBFM 

PL4 through the in vitro testing stage to be followed by mice studies before entering clinical trials  on COVID-19 patients.

About Sunshine Biopharma 

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is  engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date  have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine  Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at  McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner  of all patents and intellectual property pertaining to Adva-27a. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current expectations, forecasts, and  assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially  from those anticipated or expected, including statements related to the amount and timing of expected revenues  statements related to our financial performance, expected income, distributions, and future growth for upcoming  quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company  with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ  materially from those projected in or contemplated by the forward-looking statements due to a number of factors  detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain  growth or achieve profitability based upon many factors including but not limited to general stock market conditions.  Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC filings. We have  incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines  noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long  term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s)  based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted  at this time. 

For Additional Information Contact: 

Camille Sebaaly, CFO 

Sunshine Biopharma Inc. 

Direct Line: 514-814-0464 

camille.sebaaly@sunshinebiopharma.com 

www.sunshinebiopharma.com

For Immediate Release December 22, 2020

Montreal, Canada – (ACCESSWIRE) – Sunshine Biopharma Inc. (OTC Pink: “SBFM”), a  pharmaceutical company focused on the research, development and commercialization of  oncology and antiviral drugs today announced that its Anti-Coronavirus drug development  program is unaffected by the recent discovery of a new strain of Coronavirus in Southern  England. The new strain appears to be more easily transmissible due to a mutation in the Spike  Protein, the crown-like structure on the surface of the virus which allows it to gain entry into the  host cell. Sunshine Biopharma’s Anti-Coronavirus compound, SBFM-PL4, acts on the  Coronavirus Papain-Like Protease (PLpro) which is a non-structural protein encoded by the viral  genome and synthesized by the hijacked protein synthesis machinery of the host cell. Sunshine  Biopharma’s SBFM-PL4 inhibits PLpro and arrests viral replication. SBFM-PL4 is expected to  inhibit the PLpro of the UK variant just as well as it does the original strain since the UK strain  does not show any mutations in the PLpro gene. 

“Mutations in PLpro which could affect the binding of SBFM-PL4 to PLpro would have to be in  the essential regions of PLpro and would likely be deleterious and produce non-viable virus  particles,” said Dr. Steve N. Slilaty, CEO of Sunshine Biopharma. 

About Sunshine Biopharma’s Coronavirus Treatment 

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of  COVID-19, the current ongoing pandemic that has claimed the lives of over 1.3 million people  worldwide since it first appeared in December 2019. There are currently no drugs that can  effectively arrest replication of the virus in people who have contracted the illness. On May 22,  2020, Sunshine Biopharma filed a provisional patent application for a library of molecules which  were designed to inhibit the Coronavirus proteases, thus shutting down the ability of the virus to  multiply and cause illness. Sunshine Biopharma has since screened the library and identified a  lead Anti-Coronavirus compound (SBFM-PL4). The Company is currently conducting a series of  in vitro tests to evaluate its specific inhibitory activity of SBFM-PL4 against the SARS-CoV-2  papain-like protease (PLpro), one of two Coronavirus encoded proteases essential for viral  replication. Following the initial in vitro studies, SBFM-PL4 will be moved forward to the cell  culture testing stage and assessment in Coronavirus infected mice before entering human  clinical trials.

About Sunshine Biopharma 

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is  engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to  date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant  Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer  cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to  be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine  Biopharma is owner of all patents and intellectual property pertaining to Adva-27a. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current expectations, forecasts, and  assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ  materially from those anticipated or expected, including statements related to the amount and timing of expected  revenues statements related to our financial performance, expected income, distributions, and future growth for  upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by  the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain  events could differ materially from those projected in or contemplated by the forward-looking statements due to a  number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not  be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock  market conditions. Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC  filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as  new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the  near and long term. Additional service offerings may expose us to additional legal and regulatory costs and  unknown exposure(s) based upon the various geopolitical locations we will be providing services in, the impact of  which cannot be predicted at this time. 

For Additional Information: 

Sunshine Biopharma, Inc. 

Camille Sebaaly, CFO 

Direct Line: 514-814-0464 

camille.sebaaly@sunshinebiopharma.com 

www.sunshinebiopharma.com

For Immediate Release December 8, 2020

Montreal, Quebec, Canada — (ACCESSWIRE) — Sunshine Biopharma Inc. (OTC PINK:  “SBFM”), a pharmaceutical company focused on the research, development and  commercialization of oncology and antiviral drugs, today announced that it has ordered a new  batch of Adva-27a from its manufacturer in China. The material will be delivered to the  laboratories of Sunshine Biopharma’s drug development partner in Montreal (Canada). 

Sunshine plans to use the material to conduct testing on various types of cancer cells that  overproduce Topoisomerase II (TopII). Following these cell culture studies, Sunshine will  proceed to performing studies on mice harboring tumors of human origin with TopII  amplification. TopII is an essential cell cycle enzyme that is amplified in approximately 4% of all  human cancers. 

“All cancer types that have amplification of the Topoisomerase II gene are potential new targets  for our Adva-27a,” said Dr. Steve Slilaty, CEO of Sunshine Biopharma. “This is an additional application for our Adva-27a beyond the original multidrug resistance indication,” he added. 

About Sunshine Biopharma 

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is  engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to  date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant  Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer  cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to  be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine  Biopharma is owner of all patents and intellectual property pertaining to Adva-27a. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current expectations, forecasts, and  assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ  materially from those anticipated or expected, including statements related to the amount and timing of expected  revenues statements related to our financial performance, expected income, distributions, and future growth for  upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by  the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain 

events could differ materially from those projected in or contemplated by the forward-looking statements due to a  number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not  be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock  market conditions. Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC  filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as  new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the  near and long term. Additional service offerings may expose us to additional legal and regulatory costs and  unknown exposure(s) based upon the various geopolitical locations we will be providing services in, the impact of  which cannot be predicted at this time. 

For Additional Information Contact: 

Camille Sebaaly, CFO 

Sunshine Biopharma Inc. 

Direct Line: 514-814-0464 

camille.sebaaly@sunshinebiopharma.com 

www.sunshinebiopharma.com

For Immediate Release December 3, 2020

Montreal, Quebec, Canada — (ACCESSWIRE) — Sunshine Biopharma Inc. (OTC PINK: “SBFM”),
a pharmaceutical company focused on the research, development and commercialization of
oncology and antiviral drugs, today announced that it has paid off just over $100,000 worth of
convertible notes associated with the Company. Our Board of Directors deemed this action to be
a priority for the Company in order to mitigate dilutive conversions and maximize shareholder
value.
Sunshine Biopharma’s CFO, Camille Sebaaly stated, “We are pleased to have paid off this
convertible debt within the required time frame and will continue to work towards our overall goal
of growth from the operational side of the business.” We always have our shareholders best
interests in mind,” he added.

About Sunshine Biopharma’s Coronavirus Treatment
Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the
ongoing COVID-19 pandemic that has claimed the lives of over 1.4 million people worldwide since
it first appeared in December 2019. There are currently no drugs that can effectively arrest
replication of the virus in people who have contracted the illness. On May 22, 2020, Sunshine
Biopharma filed a provisional patent application for several molecules which were designed by
computer-aided modeling to inhibit the Coronavirus proteases, thus shutting down the ability of
the virus to multiply. Sunshine Biopharma has since completed the synthesis of four such
molecules and identified a lead compound, SBFM-PL4. In collaboration with the University of
Georgia, College of Pharmacy, the Company is currently advancing the development of SBFMPL4 through the in vitro testing stage to be followed by mice studies before entering clinical trials
on COVID-19 patients.

About Sunshine Biopharma
In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is
engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date
have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells,
including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine
Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at
McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner
of all patents and intellectual property pertaining to Adva-27a.

Safe Harbor Forward-Looking Statements
This press release may contain forward looking statements which are based on current expectations, forecasts, and
assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially
from those anticipated or expected, including statements related to the amount and timing of expected revenues
statements related to our financial performance, expected income, distributions, and future growth for upcoming
quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company
with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ
materially from those projected in or contemplated by the forward-looking statements due to a number of factors
detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain
growth or achieve profitability based upon many factors including but not limited to general stock market conditions.
Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC filings. We have
incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines
noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long
term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s)
based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted
at this time.
For Additional Information Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com

For Immediate Release December 1, 2020

Montreal, Quebec, Canada — (ACCESSWIRE) — Sunshine Biopharma Inc. (OTC PINK: “SBFM”),  a pharmaceutical company focused on the research, development and commercialization of  oncology and antiviral drugs, today announced that it has received the third tranche of funding  under the recently announced committed minimum financing of $2,000,000 with RB Capital  Partners Inc. This brings the total to $800,000 that the Company has received under this financing.  The proceeds will be used for the ongoing development of the Company’s Coronavirus Treatment  on a priority basis and the clinical development of Adva-27a, the Company’s flagship anticancer  compound targeted for pancreatic cancer. 

Brett Rosen and Deborah Braun of RB Capital Partners Inc. stated, “We continue to be amazed  by both the ingenuity and the work ethic of Sunshine Biopharma’s leadership team. This is money  well spent as every dollar is dedicated to the understanding and advancement of life-saving  medicines. RB Capital is proud to invest in a company that is relentlessly working towards  developing a Coronavirus treatment. The implications of such a treatment are boundless.”  

Sunshine Biopharma Inc. CFO, Camille Sebaaly shared, “We have a lot of important work under  way, and the continued funding by RB Capital Partners enables us to keep our focus on the  advancement of our oncology and antiviral drugs. We look forward to continue working with them  as it is clear that they truly believe in our Company’s vision.”  

About Sunshine Biopharma’s Coronavirus Treatment 

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 1.4 million people worldwide since  it first appeared in December 2019. There are currently no drugs that can effectively arrest  replication of the virus in people who have contracted the illness. On May 22, 2020, Sunshine  Biopharma filed a provisional patent application for several molecules which were designed by  computer-aided modeling to inhibit the Coronavirus proteases, thus shutting down the ability of  the virus to multiply. Sunshine Biopharma has since completed the synthesis of four such  molecules and identified a lead compound, SBFM-PL4. In collaboration with the University of  Georgia, College of Pharmacy, the Company is currently advancing the development of SBFM 

PL4 through the in vitro testing stage to be followed by mice studies before entering clinical trials  on COVID-19 patients.

About Sunshine Biopharma 

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is  engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date  have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine  Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at  McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner  of all patents and intellectual property pertaining to Adva-27a. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current expectations, forecasts, and  assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially  from those anticipated or expected, including statements related to the amount and timing of expected revenues  statements related to our financial performance, expected income, distributions, and future growth for upcoming  quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company  with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ  materially from those projected in or contemplated by the forward-looking statements due to a number of factors  detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain  growth or achieve profitability based upon many factors including but not limited to general stock market conditions.  Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC filings. We have  incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines  noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long  term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s)  based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted  at this time. 

For Additional Information Contact: 

Camille Sebaaly, CFO 

Sunshine Biopharma Inc. 

Direct Line: 514-814-0464 

camille.sebaaly@sunshinebiopharma.com 

www.sunshinebiopharma.com